Nuvation Bio Stock Target Price and Analyst Consensus
| NUVB Stock | USD 1.98 0.07 3.41% |
The current analyst and expert consensus on Nuvation Bio is Strong Buy, with 3 strong buy opinions. The current projected Nuvation Bio target price consensus is 7.50 with 4 analyst opinions. Check out Macroaxis Advice on Nuvation Bio to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.The most common way Nuvation Bio analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Nuvation Bio executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Nuvation Bio. We encourage you to use your own analysis of Nuvation Bio to validate this buy or sell advice. Nuvation Bio buy-or-sell recommendation module provides average expert sentiment on the projected Nuvation Bio target price to derive its highest and lowest estimates based on projected price volatility of 4.0874.
Lowest Forecast 6.83 | Highest Forecast 8.33 | Target Price 7.5 |
Nuvation |
It's important to approach Nuvation Bio's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Nuvation Bio Target Price Consensus
Nuvation target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Nuvation Bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Nuvation analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Nuvation stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Nuvation Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNuvation Bio Target Price Projection
Nuvation Bio's current and average target prices are 1.98 and 7.50, respectively. The current price of Nuvation Bio is the price at which Nuvation Bio is currently trading. On the other hand, Nuvation Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Nuvation Bio Market Quote on 26th of February 2025
Target Price
Analyst Consensus On Nuvation Bio Target Price
Nuvation Bio Analyst Ratings
Nuvation Bio's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Nuvation Bio stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Nuvation Bio's financials, market performance, and future outlook by experienced professionals. Nuvation Bio's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Nuvation Bio price targets
Nuvation Bio's stock target price is an estimate of its future price, usually made by analysts. Using Nuvation Bio's target price to determine if it is a suitable investment can be done through the following steps:- Look at Nuvation Bio's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Nuvation Bio's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Nuvation Bio Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Nuvation Bio is a key component of Nuvation Bio valuation and have some predictive power on the future returns of a Nuvation Bio.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nuvation Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Momentum Invested few shares | |
 | Warren Buffett Holdings Invested over 30 shares | |
 | Dividend Beast Invested over 60 shares | |
 | Banking Invested over 30 shares | |
 | SRI Sustainable Growth Invested few shares | |
 | Baby Boomer Prospects Invested over 60 shares | |
 | Driverless Cars Invested over 60 shares | |
 | Investor Favorites Invested few shares | |
 | Automobiles and Trucks Invested over 300 shares | |
 | Chemicals Invested over 30 shares | |
 | ESG Investing Invested few shares | |
 | Disruptive Technologies Invested over 20 shares |
Check out Macroaxis Advice on Nuvation Bio to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Please note, the presentation of Nuvation Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nuvation Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Nuvation Bio's management manipulating its earnings.